investigation is concerned with the direct and beta adrenoreceptor blocking actions of M & B 17,803A in the ioslated supported dog heart preparation (ISHP) under controlled hemodynamic conditions. The structure of M & B 17,803A is shown in Fig.1 . 
METHODS
The isolated supported dog heart preparation 
RESULTS
Isolated supported dog heart preparation We have observed that the ISHP is a very stable preparation and its hemodynamic functions are very well maintained over a period of 6 hours.21),24) There is no hemolysis or ventricular ectopic beats in most of the experiments, and experiments with either of these criteria are discarded. The ISHP differs from similar preparations described by Alanis et al2) and Sarnoff et al38) in 2 respects; first, the recipient heart was left in situ and second, the coronary arteries were perfused with oxygenated arterial blood at a constant flow rate.
The pH of the arterial blood remained fairly constant over the entire experimental period and ranged from 7.20 to 7.43 in the various experiments. Administration of either norepinephrine or M & B 17,803A did not have any significant effect on the arterial pH.
The hemoglobin level is an important determinant of the myocardial oxygen consumption and showed a fair degree of consistency, since it ranged from 14.0 to 14.6Gm% in the various experiments (14.6Gm%=100%). Neither the agonist nor the antagonist produced any significant effect on the hemoglobin level in any of the ISHP's.
The technique of using polarographic oxygen macroelectrodes to measure the arterial and the venous oxygen tension has been used extensively by us.21),24) We have shown earlier that the Beckman oxygen electrodes are more sensitive than the Guyton's oxygen analyzer.21) Moreover, a continuous recording of the oxygen tension enables us to accurately detect the changes taking place in pO2 at anytime. Because of the accuracy of the results and simplicity of use, we prefer the use of the oxygen electrodes to any other technique of measuring oxygen tension.
The total coronary blood flow varied between 60 and 90ml/100Gm heart wt/min in the present series, and the various recipient hearts weighed between 120 and 180Gm. A total of 6 successful ISHP's was performed.
Direct effects of M & B 17,803A in the ISHP We have observed that if the blocking agent is administered to the recipient heart, it is washed out quickly from the circulation and its high concentration might depress the myocardium suddenly.21) M & B 17,803A was, therefore, administered by a slow intravenous infusion over a period of 5min to the donor dog. The smaller dose (0.15mg/Kg) did not produce any significant effect on either the heart rate, myocardial contractile force, left ventricular peak systolic pressure, coronary artery perfusion pressure or the myocardial oxygen consumption. However, the larger dose (0.30mg/Kg) consistently produced a reduction in the heart rate, myocardial contractile force and left ventricular systolic pressure approximately 10-15min after the administration of the drug. The left ventricular end-diastolic pressure was unchanged by either dose of M & B 17,803A. The coronary artery perfusion pressure showed an upward trend, whereas there was no effect on the venous pO2 (Table I ). The effect of 0.30mg/Kg of M & B 17,803A on myocardial hemodynamics lasted throughout the experimental procedure (3 hours), although the contractile force and left ventricular peak systolic pressure showed a 40% recovery at the end of 3 hours. Note the parallel shift in the curves indicating a competitive antagonism of the norepinephrine effect. sure was also blocked in a competitive manner as indicated by a parallel shift of the dose response curve to the right (Fig.5) .
The dose-related increases in MVO2 following various doses of the catecholamine were blocked by M & B 17,803A (Fig.6) . but may be explained on the basis of the difference in the experimental design.
Most of the beta adrenergic blocking agents tested produce a blockade of all the beta receptors.12),13),25) The first "cardioselective" beta adrenoreceptor blocking agent developed was practolol.11) The cardioselective blocking agents are of great importance in the therapy of cardiac diseases.4) The structural requirements for the cardioselectivity have been reported by Ablad et al1) Bagwell and Vaughan-Williams3) and Vaughan-Williams et al. 45 ) It has been postulated that substitution of the side chain at para position of the benzene ring yields cardioselectivity, whereas either ortho or meta substitution results in a loss of such an activity. Thus, the para substituted analogs of oxprenolol and alprenolol showed cardioselectivity whereas the ortho analog of practolol had no cardioselectivity.1),45) Further, the ortho analog of 1-t-butylamino-3-(methoxyphenoxy)-2-propanol (M66527) was 3 to 4 times more potent on peripheral beta receptors and the para analog (M66368) was 2 to 4 times more potent on the cardiac beta receptors.3) It is interesting to note that M & B 17,803A has a side chain attached at the para position, which may explain the cardioselective nature as reported by several workers. However, there seems to be a discrepancy as to whether M & B 17,803A is cardioselective in its action or not. Basil et al,5) Khambatta17) and Roetscher36) are of the opinion that M & B 17,803A selectively blocks the cardiac beta receptors. On the other hand, Briant et al7) and George et al14) feel to the contrary. Cuthbert and Owusu-Ankomah8) failed to show any selectivity of action using heart rate and fall in the diastolic blood pressure following intravenous isoproterenol. Baird and Linnell4) observed a moderate degree of cardioselectivity with M & B 17,803A.
We have shown earlier 20),42) that substitution of a methyl group in the 3 position of the benzene ring yielded a potent beta receptor blocking agent (Ko 592) which had a pA2 value of 8.3 compared to the 2-methyl derivative (Ko 589; pA2 6.8) and the 4-methyl derivative (Ko 612; pA2 6.9). The 3-methyl derivative also possessed more local anesthetic activity and could effectively antagonize epinephrine-induced and ouabain-induced cardiac arrhythmias.42) In some preliminary experiments, it appears that the 4-methyl compound (Ko 612) is relatively cardioselective (Laddu, unpublished observations) . Further experiments are in progress to study whether Ko 612 does possess cardioselectivity in experimental animals. It should therefore be noted that the potency of an agent to block the beta receptors in the body does not necessarily parallel the ability to block cardiac beta receptors in a selective manner.
In recent years, several methods have been suggested to assess the potency and cardioselectivity of the beta adrenoreceptor blocking agents.4) Such screening procedures include in vitro guinea pig preparations of cardiac muscle and tracheal smooth muscle,1) dog or cat heart rate in vivo and guinea pig tracheal smooth muscle in vitro,11) dog heart rate and perfused hind limb in vivo5),35) and guinea pig heart rate and anaphylactic bronchospasm in vivo.5) The ISHP is another valuable preparation which is very helpful in screening such drugs since one can study the effect of beta receptor agonists and antagonists on the cardiac and coronary beta receptors.
We have reported earlier that agents such as practolol and LB-46 when administered intravenously to the donor dog in the ISHP produce a decrease in the myocardial oxygen consumption as observed by an increase in the venous oxygen tension.21),24),41) This effect has been referred to as the "oxygen sparing effect".19) The oxygen sparing effect does not appear to be related to a blockade of beta receptors since Sch 11973 [N-2(1-phenylisopropyl)-N'-ptoluene sulfonyl urea] and nitroglycerin which produce a similar effect in the ISHP do not block beta receptors.19),22) The exact mechanism of the oxygen sparing effect of these agents is not yet clearly known, but several investigators believe it to be due to a shift of the oxygen-dissociation curve of hemoglobin to the right.30),33) In the ISHP, M & B 17,803A did not produce any effect on the myocardial oxygen consumption in the doses used. It might be interesting to study the effect of higher doses of M & B 17,803A in the ISHP, since it has been shown that propranolol also is probably effective in a higher dose.33) However, one cannot rely too much on the possible effect observed with a larger dose of M & B 17,803A upon the myocardial oxygen consumption, since even the 0.3mg/Kg dose produced a significant decrease in the myocardial hemodynamics in the ISHP, and a still higher dose might have a greater depressant effect.
In our previous studies concerning the effects of catecholamines and adrenergic blocking agents upon the nutritional circulation in the ISHP, we have observed that vasodilators such as isoproterenol produce a reduction of the clearance of 86Rubidium.41) On the other hand, norepinephrine increased the coronary artery perfusion pressure and still produced a reduction in the capillary blood flow in the heart.23) Practolol and LB-46 which are potent beta adrenergic blocking agents and have no effect upon the coronary vascular resistance in the ISHP, produce an increase in the clearance of 86Rubidium and the capillary transport coefficient, PS.23),41) It will be interesting to study the effect of M & B 17,803A on the capillary blood flow in the ISHP.
Beta adrenergic blocking agents have been used successfully in the treatment of angina pectoris.12),21),32),34) Although propranolol has been used extensively in the clinical management of angina, its main disadvantage is the production of a direct myocardial depression.
M & B 17,803A has been reported to be effective in the treatment of angina pectoris,37) although it also possesses myocardial depressant activity in the ISHP.
It therefore appears that one needs to develop a beta receptor blocking agent that will have either a minimal or no depressant action on the heart and will still be useful in angina pectoris.
